AIM WINNERS & LOSERS: Solid State to miss forecasts on order delays
15th Nov 2024 10:33
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday. Read More
(Alliance News) - Angle PLC on Monday said its in-vitro diagnostic Parsortix system was successfully used in a non-small cell lung cancer study to help identify patients becoming resistant to treatment. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Angle PLC - Guildford, England-based liquid biopsy company - Announces it has signed an agreement with Recursion Pharmaceuticals Inc, a clinical-stage biotech company. It will launch with a fully-funded pilot study. Further details are confidential between the two companies. Read More
Angle PLC - Guildford, England-based liquid biopsy company - Celebrates research data on its Parsortix PC1 system that it says supports approval by the US Food & Drug Administration. Data was published as a peer-reviewed publication in the Journal of Experimental & Clinical Research. The study had been submitted to the FDA for De Novo clearance of the Parsortix PC1 system. The De Novo process provides a pathway to classify some novel medical devices. The study reports that the Parsortix system successfully captured and harvested circulating tumour cells (CTC) from metastatic breast cancer patient blood samples for downstream analysis using immunofluorescence and cytological evaluation. Angle says the publication validates the use of the Parsortix system for CTC isolation and harvest in metastatic breast cancer. Read More
Angle PLC - Guildford, England-based liquid biopsy company - Receives valid applications for a total of 3.6 million open offer shares from qualifying shareholders, pursuant to open offer announced on June 5. Says that the open offer has raised gross proceeds of GBP500,000 at the issue price, which will be used to strengthen Angle's balance sheet. Adds that in aggregate, GBP9.3 million gross proceeds have been raised, pursuant to the placing, subscription, and open offer. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Correcting company name in headline) Read More
(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
(Alliance News) - Stock prices in London opened higher on Friday, on the rising conviction that the afternoon's US jobs report will be softer, cooling some hawkish Federal Reserve interest rate expectations. Read More
(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations. Read More
(Correcting day of the week in the opening sentence.) Read More
(Alliance News) - Stock prices in London closed lower on Thursday, with the FTSE 100's recent rally taking a pause for breath, but not after hitting another record high. Read More
(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday. Read More
Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells. Read More
Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system. Read More